ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2026
Increased Risk of Hepatitis B Virus Reactivation in Patients with Resolved Hepatitis B Virus Infection Receiving Combination Immunosuppressive Therapy: The Role of Anti-HBs Status.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Patients with prior exposure to hepatitis B virus (HBV) (HBsAg [Hepatitis B surface antigen]-negative/anti-HBc [Hepatitis B core] immunoglobulin G (IgG)-positive) who receive immunosuppressive therapy (IST) remain susceptible to HBV reactivation (HBVr). Current clinical guidelines generally estimate HBVr risk according to the immunosuppressive potential of individual agents. However, evidence regarding the cumulative risk associated with the concurrent use of multiple agents within the same risk category remains limited. The current study investigated the effect of frequently used moderate risk IST combinations on the development of HBVr. Materials and Methods: A total of 406 HBsAg-negative/anti-HBc IgG-positive patients treated with moderate-risk IST were retrospectively analyzed. Patients were classified according to the treatment regimen into monotherapy (n = 178) and combination therapy (n = 228). HBVr was defined as either HBsAg seroconversion or the detection of HBV DNA during follow-up. The incidence of HBVr was compared between groups. Results: No significant differences were observed between the groups in baseline demographic and clinical features, including age, sex, and IST-related risk profiles. Among patients receiving combination therapy (58.7% female; mean age 62.8 ± 10.2 years), HBVr occurred in 6 patients, including 4 cases with HBV flare, whereas no reactivation occurred in the monotherapy group (62.3% female; mean age 63.6 ± 10.1 years). All patients who developed HBVr were anti-HBs-negative at baseline. HBVr occurred significantly more frequently among patients receiving combination therapy (P < .05). Conclusion: The use of combination IST and baseline anti-HBs negativity were identified as 2 important factors associated with increased risk of HBVr in HBsAg-negative/anti-HBc IgG-positive patients. In this subgroup, a clinical approach favoring antiviral prophylaxis may be considered. Further prospective studies with larger sample sizes are needed to fully elucidate this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.